Remegen Co., Ltd.
Clinical trials sponsored by Remegen Co., Ltd., explained in plain language.
-
New drug RC288 targets Hard-to-Treat solid tumors in early trial
Disease control Not yet recruitingThis study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 326 adults aged 18 to 75 with good overall health will take part.
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New drug aims to slow lung damage in autoimmune patients
Disease control Not yet recruitingThis study tests an investigational drug called telitacicept in 260 adults with connective tissue diseases (like lupus or rheumatoid arthritis) that have caused lung scarring. The goal is to see if the drug can slow the decline in lung volume over one year compared to a placebo, …
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC